다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals Inc (AUPH) 뉴스

AUPH

Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:AUPH

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/02	19:00	Business Wire	Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/05/01	19:00	Business Wire	Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/04/30	19:00	Business Wire	The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/04/16	23:48	Business Wire	UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/04/15	19:00	Business Wire	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/04/09	19:00	Business Wire	Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/08	06:44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/08	06:43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/08	06:42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/08	06:41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/01	06:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/29	22:30	Business Wire	Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/27	22:30	Business Wire	Aurinia to Participate in Upcoming Investor Healthcare Conferences	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06:35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06:33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06:31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06:29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06:27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06:19	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06:17	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/15	20:16	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/15	20:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/15	20:00	Business Wire	Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/15	05:27	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/05	22:30	Business Wire	Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/01/05	20:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/01/05	20:00	Business Wire	Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2023/12/20	20:00	Business Wire	Aurinia Submits IND Application to US Food & Drug Administration for AUR 200	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2023/11/13	20:00	Business Wire	Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2023/11/08	00:30	Business Wire	Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc

검색 관련기사 보기:NASDAQ:AUPH

1 2 3 4 5 6 7 8 9 10 다음 >>

Gold vs US Dollar

Deutsche Telekom (QX)

Invesco QQQ Trust Series 1

US Dollar vs Sterling

Bank of America

JP Morgan Chase

BNP Paribas (QX)

US Dollar vs Yen

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관